Figure 5.
Myeloid cell populations in CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice. Single-cell suspensions were prepared from the blood and lung of 1-month, 4-month, and 8-month doxycycline-treated and untreated CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice. A: The percentage number of Gr-1+CD11b+ cell population was analyzed by FACS. A representative dot-plot analysis of 4-month doxycycline-treated and untreated CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice is presented. Significant differences between doxycycline-treated and untreated groups at various time points were identified by two-way analysis of variance. Data are reported as means ± SD (n = 4 to 6). *P < 0.05. B: Absolute numbers of total Gr-1+CD11b+ cells from the lungs of doxycycline-treated and untreated CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice. Treatment duration: 1 month, 4 months, or 8 months (1Mon, 4Mon, 8Mon). Significant differences between doxycycline-treated and untreated groups at various time points were identified by two-way analysis of variance. Data are reported as means ± SD (n = 4 to 6). *P < 0.05; **P < 0.01. C: H&E staining (HE) and immunohistochemical staining with Mac 2 antibody (Mac-2) of lung tissue sections from representative 4-month doxycycline-treated or untreated CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice with inflammatory cell infiltration. Original magnification as indicated on each image. D: Kwik-Diff staining of BALF cells from 11-month doxycycline-treated or untreated CCSP-rtTA/(tetO)7-CMV-dnPPARγ bitransgenic mice. −DOX, doxycycline-untreated bitransgenic mice; +DOX, doxycycline-treated bitransgenic mice. Original magnification is indicated for each row.